Shigeru Harada
YOU?
Author Swipe
View article: Current Landscape of Urological Surgical Training: A Needs Assessment Survey in Japan
Current Landscape of Urological Surgical Training: A Needs Assessment Survey in Japan Open
Objectives To clarify the present state and issues to be resolved in urological surgical training in Japan. Methods A web‐based needs assessment survey was conducted, inviting urologists belonging to three university hospitals and 34 affil…
View article: A surgical instrument motion measurement system for skill evaluation in practical laparoscopic surgery training
A surgical instrument motion measurement system for skill evaluation in practical laparoscopic surgery training Open
This study developed and validated a surgical instrument motion measurement system for skill evaluation during practical laparoscopic surgery training. Owing to the various advantages of laparoscopic surgery including minimal invasiveness,…
View article: A prospective study of surgeons’ workloads and associated factors in real-world practice
A prospective study of surgeons’ workloads and associated factors in real-world practice Open
New technologies such as laparoscopic and robotic surgery are spreading, and there is a demand for physicians to keep up with novel methods. In contrast to the recent focus on healthcare professional burnout, the mental and physical costs …
View article: Gap analysis between trainees' subjective competencies and the competencies expected by instructors in urology: A need assessment survey in Japan
Gap analysis between trainees' subjective competencies and the competencies expected by instructors in urology: A need assessment survey in Japan Open
Objective According to the rapid progress in surgical techniques, a growing number of procedures should be learned during postgraduate training periods. This study aimed to clarify the current situation regarding urological surgical traini…
View article: Atezolizumab plus bevacizumab treatment worsens liver reserve in patients with NAFLD/NASH-associated liver cancer more than in those with non-NAFLD/non-NASH-associated liver cancer
Atezolizumab plus bevacizumab treatment worsens liver reserve in patients with NAFLD/NASH-associated liver cancer more than in those with non-NAFLD/non-NASH-associated liver cancer Open
(1) Background: Although multiple studies have reported on the therapeutic effects of Atezo+Bev for the treatment of NASH-related liver cancer, few studies have focused on its effect on liver reserve. Here, we aimed to compare the changes …
View article: Long-term effects of switching from fenofibrate to pemafibrate for asymptomatic primary biliary cholangitis (aPBC)
Long-term effects of switching from fenofibrate to pemafibrate for asymptomatic primary biliary cholangitis (aPBC) Open
The standard treatment for aPBC is to combine a fibrate with UDCA. Bezafibrate and fenofibrate are fibrates that elevate serum creatinine levels while decreasing the estimated glomerular filtration rate (eGFR). Pemafibrate is a selective p…
View article: Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma
Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma Open
Objective Multiple therapeutic agents exist for advanced hepatocellular carcinoma (HCC), but prognostic factors in second-line and subsequent therapies are unclear. Ramucirumab is a molecular-targeted agent effective against hepatocytes wi…
View article: Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study Open
To evaluate the efficacy of atezolizumab plus bevacizumab treatment in patients with hepatocellular carcinoma (HCC) previously treated with molecular targeted agents (MTAs). Thirty-one patients treated with atezolizumab plus bevacizumab fo…
View article: Successful immunomodulation in kidney transplant recipients with cytokine release syndrome after coronavirus disease
Successful immunomodulation in kidney transplant recipients with cytokine release syndrome after coronavirus disease Open
Introduction Patients with coronavirus disease, especially solid organ transplant recipients, are more susceptible to developing cytokine release syndrome than those with other viral infections. However, currently, treatment methods for su…
View article: Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis
Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis Open
Background/Aims: The addition of a fibrate to ursodeoxycholic acid (UDCA) is the standard treatment for asymptomatic primary biliary cholangitis (aPBC) with an incomplete response to UDCA. Among the fibrates, bezafibrate and fenofibrate in…
View article: Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib
Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib Open
We encountered two patients with hepatocellular carcinoma (HCC) who showed rapid progression of liver failure during sorafenib treatment. One had portal vein tumor thrombus (PVTT) and the other developed portal vein thrombosis (PVT) during…
View article: Regorafenib could cause sinusoidal obstruction syndrome
Regorafenib could cause sinusoidal obstruction syndrome Open
A 74-year-old man with advanced colon cancer was admitted to our hospital with jaundice and ascites. Four weeks before admission, he had started treatment with regorafenib because other chemotherapies had failed. Blood tests showed a chara…